A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure

Clinical Lymphoma and Myeloma

Volumn 8, Issue 1, 2008, Pages 44-51

  Candrilli, Sean ^a,b   Bell, Timothy ^a,e   Irish, William ^a   Morris, Erin ^c   Goldman, Stanton ^d   Cairo, Mitchell S ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d Medical City Dallas   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dialysis; Leukemia; Multiple myeloma; Non Hodgkin lymphoma

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RENAL REPLACEMENT THERAPY;

EID: 41349113574     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.003     Document Type: Article

References (30)

1. SEER Cancer Statistics Review 1973-1996 Overview. Bethesda, MD: National Cancer Institute; 1999.
2. Cancer in North America: 1990-1995. Incidence; vol. 1. Sacramento, CA: North American Association of Central Cancer Registries; 1999.
3. Tsokos GC, Balow JE, Spiegel RJ, et al. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218-29.
4. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133-9.
5. Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol 1995; 12:129-34.
6. Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289:1335-40.
7. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68:486-91.
8. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127:3-11.
9. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44:77-83.
10. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9:206-12.
11. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109:292-8.
12. Jeha S. Tumor lysis syndrome. Sem Hematol 2001; 38(4 suppl 10):4-8.
13. Bishop MR, Cairo MS, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Clinical Oncology. 3rd ed. Philadelphia, PA: Elsevier Churchhill Livingston; 2004:987-92.
14. Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA 1965; 193:1-6.
15. Spector T. Inhibition of urate production by allopurinol. Biochem Pharmacol 1977; 26:355-8.
16. DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274:481-6.
17. Brogard JM, Coumaros D, Franckhauser J, et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972; 17:890-5.
18. Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991; 109:281-4.
19. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19:697-704.
20. Goldman SC, Baruchel A, Leverger G, et al. Rasburicase is safe and effective in treatment and prophylaxis of hyperuricemia in children and adults with hematological malignancies at risk of tumor lysis syndrome. Proc Am Soc Clin Oncol 2002; 21:399a (Abstract 1595).
21. Coiffier B, Mounier N, Bologna S, et al. Final results of the efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 Study). Blood 2002; 100:359a (Abstract 1391).
22. Jeha S, McDonald L, Irwin D, et al. Recombinant urate oxidase (Elitek™) is safe and effective in prevention and treatment of malignancy-associated hyperuricemia in adult patients. Blood 2002; 100:556a (Abstract 2185).
23. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15:1505-9.
24. Goldman S, Holcenberg J, Finkelstein J, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis. Blood 2001; 97:2998-3003.
25. Healthcare Cost and Utilization Project (HCUP), 1998-2000: a Federal-State-Industry Partnership in Health Data. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ).
26. Gabriel, Roeder, Smith & Company (GRS). Medical Care Consumer Price Index. 2007. Available at: http://www.grsnet.com/tools/DPIData/Default.aspx. Accessed: June 1, 2007.
27. SAS Institute Inc, SAS 9.1.3. Cary, NC: SAS Institute Inc; 2003-2004.
28. Research Triangle Institute, SUDAAN (Release 9.0.1). Research Triangle Park, NC: Research Triangle Institute; 2005.
29. Brooks JM, McClellan M, Wong HS. The marginal benefits of invasive treatments for acute myocardial infarction: does insurance coverage matter? Inquiry 2000; 37:75-90.
30. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510-24.